Search filters
Filters
Clear All

Phase

  • 2
  • 2
  • 4
  • 3
  • 4

Found 4 additions trials

A listing of additions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Phase 2 Randomized Controlled Dose-titration Open-Label Study Evaluating the Safety and Efficacy of BIV201 in Addition to Standard of Care Compared to Standard of Care to Reduce the Recurrence of Ascites and Complications in Patients with Refractory Ascites Secondary to Decompensated Liver Cirrhosis

All genders
TBD
Learn More

A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopenia (ITP) patients who failed steroids

All genders
PURPOSE The overall objective is to demonstrate that the addition of ianalumab (either 3mg/kg or 9mg/kg dosage) to standard care (eltrombopag) is more effective and safer compared to the standard of care (eltrombopag) alone. Primary outcome variable is determined by the time to treatment failure which is in turn determined …
Learn More

Study to evaluate antibody response to an additional dose of COVID-19 vaccination with and without immunosuppression reduction in kidney and liver transplant recipients.

18-99 years
All genders
The purpose of the study is to find out whether an extra dose of COVID-19 study dose of vaccine will help to protect people who have had a liver or kidney transplant from COVID-19 by causing their body to make antibodies against the virus that causes COVID-19. Many transplant recipients …
Learn More

NRG-BR009 A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score

All genders
To determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 …
Learn More